Queensland company De Motu Cordis has announced plans for the next stage of developing its investigative drug-device combination for anaphylaxis.
The company, founded in Brisbane by Professor John Fraser, is developing DMC-IH1, an inhaled epinephrine product for the treatment of anaphylaxis using a dry powder inhaler.
Professor Fraser is also the founder of the Critical Care Research Group and a co-founder of the medical technology company BIVACOR.
De Motu Cordis has announced the expansion of its partnership with contract development and manufacturing organisation US-based Catalent. The partnership plans include services from drug product manufacturing and device assembly to the commercial launch of DMC-IH1.
“We are excited to build on our partnership with Catalent, one of the world’s leading CDMOs, and look forward to Catalent’s team supporting our ability to further advance DMC-IH1, through support for drug product manufacture and dry powder inhaler assembly,” said De Motu Cordis CEO Peter O’Neill. “Catalent provides DMC with a consistency of quality and manufacturing excellence in the United States to service global markets.”
